Drug details:
Molecular formula: C₄₃H₅₈N₄O₁₂

Standard name: [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate

Synonyms:

rifampin Rifadin Rimactan Rimactane Rifamycin AMP Rifaldazine Rifaprodin Rifoldin Rifa ......

Curated SMILES: CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C

Evidence for compound's anti-virulence activity:

Acinetobacter
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation.
Max phase: Preclinical (in vitro)
Publication:
Peng Q, et al., 2020. In vitro activity of biofilm inhibitors in combination with antibacterial drugs against extensively drug-resistant Acinetobacter baumannii. Sci Rep 10(1):18097.

Klebsiella
Related VF: Capsule
Target: RmpA
Drug effect: Inhibits the transcription of rmpA and rmpA-regulated cps genes and reduced the production of CPS.
Max phase: Preclinical (in vitro)
Publication:
Namikawa H, et al., 2019. Discovery of anti-mucoviscous activity of rifampicin and its potential as a candidate antivirulence agent against hypervirulent Klebsiella pneumoniae. Int J Antimicrob Agents 54(2):167-175.